Home / Contract Awards / FDA Selects Four Firms to Develop Automated Biological Product Reporting Methods

FDA Selects Four Firms to Develop Automated Biological Product Reporting Methods

The Food and Drug Administration has awarded four companies contracts worth up to $75M each to develop automated methods for reporting adverse drug events.

IBM (NYSE: IBM), Acumen, Dovel Technologies and IQVIA Government Solutions will use artificial intelligence, machine learning, natural language processing and other automation techniques to create data collection and analysis systems for the FDA’s Center for Biologics Evaluation and Research, the agency said Thursday in a FedBizOpps notice.

FDA requires each contractor to offer indirect access to medical information of U.S. patients, including administrative and claims data and electronic health records.

The indefinite delivery/indefinite quantity contracts have a five-year ordering period.

The agency also selected the four companies to develop surveillance tools as part of the Biologics Effectiveness and Safety Initiative.

Check Also

Former GovernmentCIO Exec Aaron Betz Joins ARServices as Business Dev’t VP

Aaron Betz, former vice president of business development at GovernmentCIO, has assumed the same role at information technology consultancy ARServices. He brings 33 years of government and industry experience in the management and business development areas.

Eric Peterson Named IBA Federal IT Services VP in Series of Exec Moves

Eric Peterson, a veteran business development leader, has joined Irving Burton Associates as vice president of federal information technology services.